Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005879 · ClinicalTrials.gov registry record · Phase 2
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
NCT00005879 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 199 participants.
The verdict
NCT00005879, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of LY353381 may be an effective way to prevent the development of breast cancer in women who have hyperplasia. PURPOSE: Randomized phase II trial to study the effectiveness of LY353381 in preventing breast cancer in women who have hyperplasia.
Interventions
- DRUG Placebo
- DRUG arzoxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2000-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005879
The ClinicalTrials.gov registry entry for NCT00005879 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00005879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005879 about?
NCT00005879 is a clinical study titled "LY353381 in Preventing Breast Cancer in Women With Hyperplasia". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of LY353381 may be an effective way to prevent the development of breast cancer in women who have hyperplasia. PURPOSE: Randomized phase II trial to study the effectiven...
What is the current status of trial NCT00005879?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2000-08. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00005879?
The interventions under investigation include: Placebo (DRUG), arzoxifene (DRUG).
Who is sponsoring clinical trial NCT00005879?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.